Court Challenges Brazil’s Pharmacy Data-for-Discount Model
A ruling against Drogasil questions whether retailers can make lower prices depend on customers handing over…
B3 · Bovespa
RADL3 Raia Drogasil
Profile
Financials
Related news on Raia Drogasil
RD Saúde Leads Brazil Pharmacy Ranking; See the Full List
Sales hit R$118.5 billion in 2025, up 14.9%, as the ranking remains largely unchanged, underscoring scale…
RD Saúde to Invest $20 Million in Paraná Logistics Hub
New distribution center in Londrina will store up to 20 million items and is expected to…
RD Saúde Profit Hits R$362 Million in 4Q25 as Digital Sales Surge
Retail pharmacy giant posts strong revenue growth and market-share gains as GLP-1 drugs and omnichannel sales…
Brazil Retail Draws Global Interest, but Macro Uncertainty Caps Conviction
BTG Pactual says foreign investors remain engaged in retail sector, but capital is narrowing to a…
XP Lifts Raia Drogasil to Buy as GLP-1 Drives New Growth Cycle
Obesity and diabetes drugs, coming generics and HPC overhaul push price target to $6.30 by 2026.
Brazil’s 3Q25 Corporate Season Reveals a New Phase: Discipline, Repair and Selective Growth
The Brazil Stock Guide mapped more than 60 earnings calls in an unprecedented, highly accurate editorial…
Brazilian Companies Beat on Revenue but See Profit Squeeze in 3Q25, BTG Says
Operational strength contrasts with a sharp profit contraction as high rates hit domestic sectors.
RD Saúde Rides GLP-1 Wave as Weight-Loss Drugs Power Growth
GLP-1 weight-loss and diabetes drugs are reshaping RD Saúde’s business, positioning the retailer for a new…
Market data by TradingView. Informational only — not investment advice.